Meclizine: Difference between revisions
| Line 16: | Line 16: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: Excretion in breast milk unknown | *Lactation: Excretion in breast milk unknown | ||
*Renal Dosing: n/a | *Renal Dosing: n/a | ||
*Hepatic Dosing: n/a | *Hepatic Dosing: n/a | ||
*'''[[High-risk geriatric medication]]!''' | |||
==Contraindications== | ==Contraindications== | ||
Latest revision as of 23:16, 20 May 2026
General
- Type: Antihistamine, H1 antagonist
- Dosage Forms: 12.5, 25, 32mg oral tablet; 25mg oral chewable tablet
- Common Trade Names: Univert, Vertin-32, Dramamine less drowsy, Motion-Time
Adult Dosing
Vertigo
- 25mg PO QID
Motion sickness
- 25-100mg PO 1 hour before activity. May repeat q24h
Pediatric Dosing
- >= 12 yrs old: Adult dosing
- < 12 yrs: No dosing specified in drug insert
Special Populations
- Pregnancy Rating: B
- Lactation: Excretion in breast milk unknown
- Renal Dosing: n/a
- Hepatic Dosing: n/a
- High-risk geriatric medication!
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- CNS depression
- Caution in asthma, glaucoma, BPH, pyloric obstruction
Common
- Drowsiness, fatigue
Pharmacology
- Onset: 1 hour
- Half-life: 5 hours
- Metabolism: Hepatic
- Excretion: Urine and feces
- Mechanism of Action: Central anticholinergic; blocks chemoreceptor trigger zone. Decreases middle ear excitability, blocks vestibular-cerebellar pathways
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Vertigo | 25 mg QID | Antihistamine (vestibular suppressant) | PO | Adult |
See Also
References
Lexicomp